Welcome to our dedicated page for Genelux news (Ticker: GNLX), a resource for investors and traders seeking the latest updates and insights on Genelux stock.
Genelux Corporation develops oncolytic viral immunotherapies for cancer as a late clinical-stage immuno-oncology company. News about GNLX commonly centers on Olvi-Vec (olvimulogene nanivacirepvec), its proprietary modified vaccinia virus, and clinical development in platinum-resistant or refractory ovarian cancer, small cell lung cancer and non-small cell lung cancer.
Company updates also cover quarterly financial results, research and development spending, cash runway disclosures, equity financing activity, conference presentations and management changes tied to clinical development and medical strategy. Genelux has also disclosed an exclusive Greater China license for Olvi-Vec with Newsoara.
Genelux (NASDAQ: GNLX) reported Q1 2026 results and program updates. The randomized Phase 3 OnPrime/GOG-3076 topline data for Olvi-Vec in platinum-resistant/refractory ovarian cancer is expected in 2H 2026. Cash and equivalents were $26.3M as of March 31, 2026, expected to fund operations into Q1 2027. Q1 R&D was $5.8M, G&A $3.4M, and net loss was $8.9M ($0.20 per share). Preliminary systemic lung cancer data show tumor responses and disease control signals; additional 2026 updates expected.
Genelux (NASDAQ: GNLX) reported fourth-quarter and full-year 2025 results and business updates on March 19, 2026. Key items: Phase 3 OnPrime/GOG-3076 topline data for intraperitoneal Olvi-Vec expected in 2H26. Interim systemic lung data showed partial responses in SCLC and early activity in NSCLC. The company had $33.1M pro forma cash as of Dec 31, 2025 (including $18.5M net from a January 2026 offering) and expects funding into 1Q27.
R&D and G&A rose modestly year-over-year; net loss was $32.1M (2025). Additional 2026 clinical updates and dose-finding results are expected.
Genelux (NASDAQ: GNLX) will participate in two investor conferences in late February and early March 2026. Management will deliver a virtual fireside chat on Feb 25, 2026 at 11:20 a.m. ET and a live presentation on Mar 2, 2026 at 2:30 p.m. ET in Boston.
Live webcasts and archived replays will be available on the company’s Events & Presentations investor relations webpage.
Genelux (NASDAQ: GNLX) will host a virtual fireside chat with Titan Partners on January 19, 2026 at 9:00 a.m. PT. Participants include Thomas Zindrick (President, CEO and Chairman), Matt Pulisic (CFO), and Dr. Jason Litten (CMO), with Boris Peaker, PhD of Titan Partners moderating. A live webcast will be available on the company investor relations website and an archived replay will be posted after the event.
Genelux (Nasdaq: GNLX) priced an underwritten public offering of 6,666,667 common shares at $3.00 per share, for gross proceeds of approximately $20.0 million before underwriting discounts, commissions and expenses. The company granted a 30-day option for the underwriter to buy up to an additional 1,000,000 shares at the public price less discounts. Net proceeds are expected to be used for general corporate purposes, including R&D, clinical trial expenses, capital expenditures and working capital. The offering is expected to close on or about January 9, 2026, subject to customary closing conditions.
Genelux (Nasdaq: GNLX) announced a proposed underwritten public offering of its common stock on January 7, 2026. The company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares sold. All shares will be offered by Genelux and the offering is subject to market and customary closing conditions, so completion, size and terms are not assured. Lucid Capital Markets is the sole book-running manager. The offering will be made from an effective shelf registration filed February 2, 2024 and declared effective February 13, 2024, with a preliminary prospectus supplement to be filed with the SEC.
Genelux (NASDAQ: GNLX) reported interim systemic Olvi-Vec data from ongoing lung cancer trials as of December 2025. In Phase 1b/2 SCLC (9 evaluable patients) the overall response rate was 33% (3/9), with two partial responses in the highest tested dose cohort showing ~55% and ~85% tumor shrinkage; disease control rate was 67% (6/9). In Phase 2 VIRO-25 NSCLC (5 evaluable patients) disease control rate was 60% (3/5) with tumor changes of +8.9%, -18.9%, and -22.7%. Olvi-Vec was reported as generally well tolerated. Additional lung cancer readouts and Phase 3 ovarian topline data expected throughout 2026.
Genelux (NASDAQ: GNLX) appointed Jason Litten, M.D. as Chief Medical Officer, effective January 2, 2026.
Dr. Litten will oversee clinical development and medical strategy as Genelux advances Olvi-Vec toward upcoming pivotal readouts in ovarian and lung cancer. He brings over 20 years of oncology development experience across biologics, small molecules, and cell therapies, with prior CMO roles at Chimeric Therapeutics and Artiva and senior positions at Juno, Clovis, and Amgen. In connection with his hire, Genelux granted an inducement stock option for 275,000 shares under the 2023 Inducement Plan, exercisable at the closing price on the grant date and vesting over four years (25% at one year, then monthly over 36 months).
Genelux (NASDAQ: GNLX) announced that Thomas Zindrick, President, CEO and Chairman, and Matt Pulisic, CFO, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 12:00 p.m. ET in New York.
A live webcast will be available during the event and an archived replay will be posted on the company's investor website at https://investors.genelux.com/.
Genelux (NASDAQ: GNLX) reported third quarter 2025 results and clinical updates on Nov 5, 2025. The company held $21.0 million in cash, cash equivalents, short-term investments and restricted cash as of Sept 30, 2025, which management expects will fund operations into the third quarter of 2026. Topline data from the OnPrime Phase 3 ovarian cancer registrational trial is now anticipated in the second half of 2026. Additional interim data from two systemically delivered Olvi-Vec lung cancer trials are expected in Q4 2025 and through 2026. Q3 2025 net loss was $8.0 million (loss per share $0.21); R&D was $4.7 million and G&A was $3.5 million.
Key program notes: OnPrime remains enrolling in the U.S.; the Independent Data Monitoring Committee has recommended continuation; company believes positive PFS without OS decrement could support traditional FDA approval based on a Type D meeting.